Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

TON - February 2021 Vol 14, No 1

In this issue of The Oncology Nurse-APN/PA (TON), we provide our readers with a variety of articles aimed at helping them stay informed on important issues facing nurses, navigators, and advanced practice providers.
Penn Medicine’s Abramson Cancer Center (ACC) is comprised of 6 hospitals and many facilities located in the tristate area of Pennsylvania, New Jersey, and Delaware.
When it comes to gathering and assessing social determinants of health (SDoH) as part of a medically appropriate history and examination, it is necessary to employ 5 key strategies, said Allysceaeioun D. Britt, PhD, MPH, Interim Vice President, Office of Faculty Affairs and Development, Meharry Medical College, Nashville, TN, in a presentation during the virtual 2020 Healthcare Administration Alliance Conference.
The COVID-19 pandemic has exposed many of the cracks in our healthcare system.
Helping patients with cancer achieve optimal health status can present special challenges when their basic needs such as food security, housing, and transportation are not being met.
A post-hoc analysis of a pivotal clinical trial showed that belantamab mafodotin-blmf (Blenrep), a first-in-class antibody–drug conjugate targeting B-cell maturation antigen, induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Financial toxicity can have a negative effect on outcomes for patients with cancer.
Approximately two-thirds of patients with chronic-phase chronic myeloid leukemia (CML) achieved a major cytogenetic response to the novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI) vodobatinib, regardless of whether they had received previous treatment with ponatinib (Iclusig), according to findings from a recent phase 1 clinical trial.
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in applying the use of targeted therapies in the treatment of patients with cholangiocarcinoma (CCA).
Page 1 of 2
Results 1 - 10 of 12